which can act on both programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) receptors, and can multivalently bind to T cells that coexpress PD-1 and CTLA-4 in the tumor microenvironment. This evidence concerns the gene PDCD1 and neoplasm.